Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.

Literature DB >> 3143585

Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.

K V Rolston¹, D H Ho, B LeBlanc, G Gooch, G P Bodey.

Abstract

The in vitro activity of temafloxacin, a new difluoro quinolone agent, against 725 bacterial isolates representing 32 species was evaluated in comparison with that of ciprofloxacin. Temafloxacin inhibited the majority of Enterobacteriaceae isolates at a concentration of less than or equal to 0.5 microgram/ml. It was also extremely active against Acinetobacter spp. and Aeromonas hydrophila. Its activity was 2-8 fold less than that of ciprofloxacin against most gram-negative isolates. Methicillin-susceptible and methicillin-resistant Staphylococcus aureus, coagulase-negative Staphylococcus spp., Streptococcus spp., Listeria monocytogenes, Bacillus spp. and group JK corynebacteria were inhibited at concentrations equal to that of ciprofloxacin.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1988 PMID： 3143585 DOI： 10.1007/bf01964255

Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN： 0934-9723 Impact factor: 3.267

9 in total

1. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors: J S Wolfson; D C Hooper
Journal: Antimicrob Agents Chemother Date: 1985-10 Impact factor: 5.191

2. In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.

Authors: K V Rolston; D H Ho; B LeBlanc; G P Bodey
Journal: Antimicrob Agents Chemother Date: 1987-01 Impact factor: 5.191

3. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Authors: J E Karp; W G Merz; C Hendricksen; B Laughon; T Redden; B J Bamberger; J G Bartlett; R Saral; P J Burke
Journal: Ann Intern Med Date: 1987-01 Impact factor: 25.391

4. In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent.

Authors: N X Chin; V M Figueredo; A Novelli; H C Neu
Journal: Eur J Clin Microbiol Infect Dis Date: 1988-02 Impact factor: 3.267

5. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.

Authors: L J Eron; L Harvey; D L Hixon; D M Poretz
Journal: Antimicrob Agents Chemother Date: 1985-08 Impact factor: 5.191

6. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.

Authors: A W Dekker; M Rozenberg-Arska; J Verhoef
Journal: Ann Intern Med Date: 1987-01 Impact factor: 25.391

7. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

Authors: D J Hardy; R N Swanson; D M Hensey; N R Ramer; R R Bower; C W Hanson; D T Chu; P B Fernandes
Journal: Antimicrob Agents Chemother Date: 1987-11 Impact factor: 5.191

8. Enoxacin in the treatment of lower respiratory tract infections.

Authors: F Philip-Joet; J Nourrit; Y Frances; A Arnaud
Journal: J Antimicrob Chemother Date: 1988-02 Impact factor: 5.790

9. Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units.

Authors: S Lauwers; W Vincken; A Naessens; D Pierard
Journal: J Antimicrob Chemother Date: 1986-04 Impact factor: 5.790

9 in total

10 in total

Review 10. Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.

Authors: R Janknegt; Y A Hekster
Journal: Pharm Weekbl Sci Date: 1989-04-28

10 in total

Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.

1. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

2. In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.

3. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

4. In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent.

5. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.

6. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.

7. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

8. Enoxacin in the treatment of lower respiratory tract infections.

9. Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units.

1. Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.

2. Activity of temafloxacin against respiratory pathogens.

3. Pharmacokinetics of temafloxacin in humans after single oral doses.

4. Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.

5. In vitro activity of cefpodoxime against bacterial isolates obtained from patients with cancer.

6. Pharmacokinetics of temafloxacin in patients with liver impairment.

7. Effect of cimetidine on the pharmacokinetics of temafloxacin.

Review 8. Fluoroquinolone antimicrobial agents.

9. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii.

Review 10. Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.